INTRODUCTION
The use of testicular or epididymal sperm in combination with intracytoplasmic sperm injection opened a new era in the treatment of azoospermic males and they have had the opportunity to become biological fathers (1, 2) . However, in patients where no spermatozoa have been found after surgical sperm retrieval methods such as testicular sperm extraction (TESE) and microepididymal sperm aspiration (MESA), even after very extensive testicular biopsies, these trials did not come to a conclusion, and recently spermatid injections have been proposed for these patients (3). Wanderzwalmen et al. (4) first demonstrated fertilization and embryo formation with spermatid injection, and thereafter, using elongating or elongated spermatid (ELSI), round spermatid (ROSI), or round spermatid nucleus (ROSNI) injection, a few ongoing pregnancies and births have been reported (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . The use of more mature forms of spermatids, mainly spermatids that are in the elongation phase, has been reported to give better fertilization and implantation rates compared to more immature round spermatids and they can preferably be used for ICSI in the lack of spermatozoa (19) (20) (21) . The higher fertilization and pregnancy rates obtained with elongating or elongated spermatids suggest that most of these cells are viable and genetically normal (21) . On the other hand, to differentiate and recognize a round spermatid among other cell types is difficult and to ensure their viability and genetic normality is nearly impossible. Therefore, round spermatid injection is generally associated with poor fertilization and embryonic development rates and the clinical outcome is dramatically lower (22, 23) . To our knowledge, to date there have been eight pregnancies reported after round spermatid injection: three using ejaculated spermatids (5) (6) (7) 14) and five using spermatids extracted from testicular material (11, 19, 20) . However, Prapas et al. (21) reported that, in all these cases, the male patient had a history of the presence of elongated spermatids or spermatozoa in the ejaculate or in the diagnostic testicle biopsy, with no elongated spermatids or spermatozoa having been recovered at the moment of treatment. In contrast, in all cases where the male-factor patient showed a complete absence of elongated spermatids or spermatozoa in previous ejaculate or diagnostic testicle biopsy, no pregnancy has been reported so far using round spermatids.
Despite the availability of these encouraging results, round spermatid injection is still a matter of debate and our previous report on round spermatid injection in 20 patients (19) did not achieve any clinical pregnancy as reported by many others (22, 23) . Therefore, we stopped our spermatid injection program after these unsuccessful results until 1998. However, according to our knowledge, in all these studies embryo transfers were carried out on day 2 or 3 after round spermatid injection and the results of embryo development up to the blastocyst stage and of embryo transfer at blastocyst stage were not well known. The developments in human embryo culture media (24) and increasing popularity of delayed embryo transfer, which improves the implantation and pregnancy rates in human IVF program (25) (26) (27) , have encouraged us to extend the culture of embryos after round spermatid injection to see the progression rate of ROSIderived embryos to the blastocyst stage and its clinical value after embryo transfer.
In this study, we report our preliminary results with extended culture of embryos after round spermatid injection.
MATERIALS AND METHODS
This study was performed at a private IVF unit between June 1 and December 31, 1999 . During this period, 38 men with azospermia applied to our IVF program. After documenting azoospermia in at least two semen analyses, all patients underwent a complete physical and genital examination by urologists. Scrotal ultrasonography to evaluate the testicular volume and hormone analysis including FSH, LH, prolactin, and testosterone were carried out. Previous biopsy results of testis and karyotype analysis were recorded and all patients, if it was not available, had given blood samples for karyotype analysis; Y chromosome microdeletions were also studied. After these investigations, 20 patients were diagnosed to have obstructive azoospermia, and in the remaining 18, nonobstructive azoospermia was the etiological factor. All patients were informed about their chance of having spermatozoa and also their chance of achieving a pregnancy.
All of the cycles in the study were down-regulated using long-protocol gonadotropin releasing hormone agonist (GnRHa) and 600 µg buserelin acetate as a nasal spray (Suprecur; Hoechest, Turkey), starting in the luteal phase of the preceding cycle day 21. The dose was halved when pitiutary supression was documented by E 2 levels <50 pg/ml and the absence of an ovarian cyst on transvaginal ultrasound examination. Then ovarian stimulation was achieved by stepdown administration of pure FSH [Metrodin (Serono, Istanbul) or Follegon (Organon, Istanbul); the starting dose ranged between 150 and 600 IU daily. To trigger the final follicular maturation, 5000-10,000 IU of hCG [Pregnyl (Organon) or Profasi (Serono)] was administered to each patient when there were at least three follicles >16 mm in diameter and oocyte pickup was planned 34-36 hr later.
In all cycles, particularly cases with nonobstructive azoospermia, the TESE procedure was carried out before oocyte collection. If no spermatozoa were found and if the patient did not accept spermatid injection, oocyte pickup was canceled, but if there was an ovarian hyperstimulation risk, it was carried out. After micrusurgical sperm aspiration (MESA), percutaneous sperm aspiration (PESA), or a testicular sperm extraction procedure (TESE), sperm were recovered in all cases with obstructive azoospermia (n = 20), whereas in 18 patients with nonobstructive azoospermia, after the TESE procedure, spermatozoa were recovered in 9 and only round spermatids were found in 7 patients. In two of the patients, there were neither elongated nor round spermatids. For TESE, an open-biopsy technique under local anesthesia was applied. The testicular tissue obtained was placed in a petri dish containing washing medium with heparin and HEPES such as Aspiration-100 (Scandinavian IVF Science, Göteborg, Sweden) and then transferred in a Falcon 2003 tube containing 1 ml of Gamete 100 medium (Scandinavian IVF Science) and divided into small volumes. It was gently crushed between two pincettes in a petri dish containing Gamete 100 to obtain a suspension. The suspension was transferred to another Falcon 2003 tube and rotated for 50-60 sec with a vortex mixer. Then, in a Falcon 3802 petri dish containing 5 ml medium, it was examined at 200-400 × magnification under a Hoffman modulator mounted inverted microscope. If spermatozoa or spermatids were observed, the suspension was centrifuged on a two-layer (70-90%) Percoll gradient (Sigma Chemical Co., St. Louis, MO) and the testicular tissue solution was kept in an incubator at 37
• C with 5% CO 2 until the injection procedure. If no spermatozoa or spermatids were found, more testicular tissue samples (up to eight from both testes) were obtained in all cases.
The determination of round spermatids is a difficult procedure, and in our study this was done using only morphological criteria. It depends mainly on the differentiation of round spermatids from other round cells including Sertoli cell nuclei, spermatogonia, primary and secondary spermatocytes, erythrocytes, leukocytes, monocytes, and lymphocytes. Morphologically, round spermatids are 8-9 µm in diameter, slightly larger than erythrocytes; they have a smooth outline and a round nucleus, with a regular zone of cytoplasm surrounding the nucleus; and some of them include a developing acrosomal granule as a bright spot adjacent to the spermatid nucleus.
Those seven patients in whom only round spermatids were found after TESE were again counseled about the very poor outcome of round spermatid injection and informed that no clinical or ongoing pregnancy had been achieved in our program and only one biochemical pregnancy had been obtained after round spermatid injection (19) . After providing this detailed information, we invited them to leave all their embryos in extended culture for up to 5 to 6 days. If fertilization and embryo development could be achieved, and if any embryos reaching the blastocyst stage were available, they were used for embryo transfer. One of these patients chose to stop treatment, and the other six patients, who were well aware of all possibilities, accepted our suggestion. Patients with obstructive or nonobstructive azospermia from whom spermatozoa were obtained were also counseled about blastocyst-stage transfer, and in those patients selecting delayed embryo transfer, embryos were cultured up to the sixth day. The study was also approved by the Human Investigation Committee of the Hospital and informed consent was given by all participants.
After the decision for round spermatid injection and extended culture of embryos, oocytes were recovered transvaginally with ultrasound guidance 35-36 hr after hCG injection under intravenous total anesthesia with Propofol (Zeneca, Istanbul). For all steps of gamete and embryo handling and culture, a spectrum of commercial media obtained from Scandinavian IVF Science was used, and no serum was added in any step. After collection, all oocytes were incubated singly, before and after round spermatid injection, in 50-µl droplets of IVF-50, under Ovoil-150. Before the injection, oocytes were denuded using a hyaluronidase solution prepared from Hyase-10X, and the injection procedure was performed 2-3 hr after oocyte recovery. For injection, spermatozoa or spermatids were aspirated from the pellet or Percoll suspension with a 10-µm pipette and transferred into an injection dish containing a droplet of 5 µl Gamete 100 medium. Then they were aspirated one by one from the droplet and transferred into a polyvinylpyrrolidone droplet (ICSI-100; Scandinavian IVF Science). Spermatids were aspirated into a 7-µm injection pipette, and after vigorous aspiration of the ooplasm to facilitate activation, they were injected into the oocytes. Injected oocytes were then placed into individual droplets in a petri dish and were incubated at 37
• C under a humidified atmosphere of 5% CO 2 in air in Hereaus (Germany) incubators (Models 6220 and BB16). Fertilization was assessed 16-19 hr after the injection procedure, and it was accepted as normal when two clearly distinct pronuclei containing nucleoli were present. After 24 hr in in vitro culture, on day 2, the state of embryo cleavage and quality of embryos were assessed. Culture of embryos was continued in IVF-50 medium droplets under Ovoil-150 till day 3. On day 3, the medium was changed to S2 medium, which was used till to the transfer. Embryos were reevaluated every day and the medium was freshened every 24 hr. Blastocoele formation, expansion, zona thinning, hatching, and cell structure and distribution of the trophoectoderm were documented starting on day 5. Full expansion, zona thinning, hatching, and well-defined borders and a homogeneous distribution of trophoectoderm cells were accepted as favorable signs, and blastocysts carrying these features were accepted as good and fair, whereas others were defined as poor. All transfers at the blastocyst stage were done using G2.2 medium and a Frydman transfer catheter (CCD, Ref.
No. 1307000, France). Luteal-phase support was provided by 400 mg transvaginal micronized progesterone (Utrogestane; Laboratoire Besins Iscovesco, France) daily. Two days after embryo transfer the E 2 level was measured in all patients; if it was low, 1500-2000 IU single-dose hCG was administered for corpus luteum rescue. A serum β-hCG level higher than 25 mIU/ml was considered a positive pregnancy test on day 11 or later after the transfer.
Statistical analysis was carried out using SPSS for MS Windows, and nonparametric tests for two independent samples and the chi-square test or Fisher's exact test were used where appropriate. A P value <0.05 was considered statistically significant.
RESULTS
Spermatozoa were recovered in all 20 patients with obstructive azoospermia whereas in the 18 patients with nonobstructive azoospermia, spermatozoa were recovered in 9 and only round spermatids were found in 7 patients. In two of the patients, there were no elongated or round spermatids and oocyte pickup was canceled. After ICSI, as a fertilization rate of 72.2 vs 71.1% and a pregnancy rate of 44.4% (4/9) vs 45% (9/20) were obtained in the nonobstructive azoospermia group and obstructive azoospermia group, respectively, these two groups, in which spermatozoa were retrieved from the testis or epididymis, were evaluated together and classified as the spermatozoa group. In seven patients with only round spermatids available, one patient did not accept the round spermatid injection and six patients remained for round spermatid injection (ROSI group). As our previous study (19) revealed a very poor outcome with spermatid injection and day 3 transfer, the purpose of this study was to evaluate the progression rate of embryos to the blastocyst stage and the clinical value of blastocyst-stage transfer after ROSI. All of these men had had azoospermia in previous and current sperm analyses, and no spermatozoa were documented in previous or current testicular biopsies. Table I lists the data on individual patients in the ROSI group. Although both groups were similar regarding patient and cycle characteristics including age, FSH level, estradiol value on hCG day, and number of oocytes retrieved and injected, the mean number of fertilized oocytes and mean number of embryos available on day 3, and also the fertilization rate and mean number of good-quality embryos on day 3, mainly grade 1 or 2, were statistically significantly higher in the spermatozoa group than the ROSI group (Table II) . Twenty-one patients in the spermatozoa group underwent embryo transfer on day 3 and 10 pregnancies were achieved, for a pregnancy rate of 47.6% in these patients. On the other hand, for all six patients in the ROSI group and eight patients in the spermatozoa group, no embryo transfers were performed on day 3 and all available embryos were followed by extended culture up to the sixth day. After oocyte pickup, in the ROSI group, a total of 78 oocytes was recovered and 60 metaphase II oocytes were injected. Seventeen of these were fertilized (28.3%), while the remaining 43 were intact or degenerated. Among 14 embryos available on day 3, 9 were grade 1 or 2 and five embryos reached the blastocyst stage on day 6, of which only two were good quality: one in the hatching stage and one with full expansion (Table III) . Compared to the spermatozoa group, the number of arrested embryos was significantly higher and the number of blastocyst-stage embryos and number of good-quality blastocysts were significantly lower in the ROSI group (Table IV) . No blastocysts developed in two of these cycles and embryo transfer was not possible. In the remaining four cycles, after at least one blastocyst transfer, no pregnancy was achieved, whereas in eight cycles with extended culture in the spermatozoa group, embryo transfers were achieved in all and three pregnancies, for a pregnancy rate of 37.5%, were obtained after blastocyst transfer.
DISCUSSION
After obtaining some encouraging results with spermatid injection in mice and rabbits (28, 29) , spermatid injection into human oocytes was first suggested by Edwards et al. (3) . Wanderzwalmen et al. (4) first demonstrated fertilization and embryo formation with spermatid injection, and thereafter, using elongating or elongated spermatids, round spermatids, or round spermatid nucleus injection (ROSNI), a few ongoing pregnancies and births have been reported (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . However, many of these pregnancies obtained using more mature forms of spermatids including elongating or elongated ones and pregnancies obtained by round spermatid injection were achieved mainly in patients with past or present existence of spermatozoa or elongated spermatids in their ejaculates or diagnostic testicle biopsies, which are the signs of incomplete failure of spermiogenesis (21, 22) . On the other hand, in patients with complete failure of spermiogenesis, round spermatid injection resulted in very low fertilization and embryonic development rates. Although Fishel et al. (9) reported that there was no difference in the quality of embryos resulting from ROSI compared with conventional ICSI, Wanderzwalmen et al. (20) showed that the number of good-quality embryos available for transfer after ROSI was very low. Ghazzawi et al. (22) applied round spermatid injection in 87 patients with complete failure of spermiogenesis and compared the results with those obtained from 93 patients with mature epididymides or spermatozoa. The fertilization rates (22 vs 72%) and number of embryos developed (62 vs 95.8%) were significantly lower, whereas the number of arrested embryos (38 vs 4.2%) was significantly higher in the round spermatid injection group. In that study, no grade 1 or 2 embryos were obtained after round spermatid injection (0 vs 56%) and all the embryos available for transfer were of poor quality (100 vs 44%). The number of transfer cycles (46 vs 91%) was also significantly lower and no pregnancies were obtained after ROSI, whereas it was 20% in the spermatozoa group. Our experience with ROSI is also similar to the results of Ghazzawi et al. (22) . In our first study (19) , we applied round spermatid injections in 20 patients, and these resulted in a fertilization rate of about 25%, three cases with total fertilization failure, and only one biochemical pregnancy after 17 embryo transfer trials. In our present study, a lower fertilization rate, 28.7%, with a significantly lower number of good-quality embryos were obtained compared with the spermatozoa group, indicating that round spermatid injection in patients with complete failure of spermiogenesis is associated with a very poor reproductive outcome.
In human IVF, delivery rates of about 14-15% were reported after the transfer of a mean number of three cleavage-stage embryos on the second or third day (30) , and these values have remained lower than that routinely achieved for animal IVF, where mainly the blastocyst-stage embryo transfer is utilized (31) (32) (33) . The development of two sequential serum-free media formulated for the culture of human zygotes to the blastocyst stage contributed considerably to human IVF, and currently, implantation rates of up to 30-50% and clinical pregnancy rates of up to 70% have been reported after extended culture of embryos and blastocyst-stage embryo transfers (34, 35) . These achievements in culture media persuaded us to perform a prospective study to evaluate the further development of embryos after round spermatid injection. In this study, after ROSI, we strongly suggested extended culture to all patients. Eight of 29 patients with spermatozoa also preferred extended culture of their embryos for blastocyst transfer. In six patients with ROSI, 64.2% of the embryos arrested, while 28.9% of the embryos arrested in the spermatozoa group, which was statistically significant (P < 0.01). The number of blastocysts developed on day 6 (35.8 vs 71.1%; P < 0.01) and number of good-quality blastocysts (14.2 vs 45.7%; P < 0.05) were also significantly lower in the ROSI group compared to the spermatozoa group. In the ROSI group, no transfer was possible due to the arrest of all embryos in two cycles, and in four transfer cycles no pregnancy was achieved. Three pregnancies (37.5%) were achieved in eight treatment cycles in the spermatozoa group. Although there was no significant difference, this was probably related to the limited number of patients. In the spermatozoa group, the higher pregnancy rate of 47.6% after day 3 transfer, versus 37.5% after day 6 transfer, could also be related to the limited number of patients with blastocyst transfer.
Yamamoto et al. (36) , using round spermatid injection in rabbits, showed a very poor embryonic development rate, and only one of nine cleaved embryos (11%) reached the blastocyst stage. In a very recent study evaluating the progression of blastocyst-stage embryos derived after ROSI in humans, Balaban et al. (37) reported a 50% fertilization rate, and 53% of the good-quality embryos (grades 1-2), and 25% of the poor-quality embryos (grades 3-4) reached the blastocyst stage. Both the fertilization and the blastocyst development rates were significantly higher than those obtained in our study. But in that study, azoospermic men in whom partial spermatogenesis failure had occurred and spermatozoa were available for injection were studied, which was different from our patient population, including only patients with complete spermiogenesis failure. After the injection of a limited amount of spermatozoa, remaining excess oocytes were injected by round spermatids in that study and those embryos were evaluated for progression to the blastocyst stage. In our study, 5 of 14 cleaved embryos (35.8%) developed from 60 injected oocytes reaching the blastocyst stage, but we do not know if all these were normally developed blastocysts, as parthenogenetic activation may also cause embryonic development up to this stage or even further (38) .
Almost all studies on round spermatid injection have clearly indicated a lower fertilization and embryo development rate, with a very low number of pregnancies. The underlying mechanisms for this have not yet been fully resolved, but there are some hypotheses including difficulties in the identification of round spermatids, technical problems causing injury to oocytes, cytoplasmic immaturity of ROS compared to their nuclei, a deficiency of oocyte activating factor, and genetic abnormalities and defects at the DNA level in round spermatids (22) . Although there are some studies indicating a strong paternal effect on embryo development and blastocyst formation, this is currently not very clear (39) . Whatever the reason, ROSI has been thought to interrupt normal fertilization and prevent normal embryonic development, although the hyphothesis of complete embryo block could not be confirmed. After all these negative impacts of ROSI, the most promising approach for these men to have their own children seems to be in vitro maturation of round spermatids (40) (41) (42) .
In conclusion, although the number of cases was too small and it is too early to reach a firm conclusion, our preliminary results show that ROSI in patients with complete failure of spermiogenesis was related to significantly lower fertilization and embryo development rates and significantly higher developmental arrest compared with the injection of spermatozoa. Although some of the embryos reached the blastocyst stage, the number of developed blastocysts and their quality were also lower than for spermatozoa, and no pregnancy was achieved after blastocyst-stage transfer in the ROSI group. These results suggest a developmental failure in embryos preventing successful implantation after ROSI.
